Inhaled pharmaceutical products maker Vectura has agreed a new US collaboration with a leading international pharmaceutical company. Under the terms of this agreement, Vectura's unnamed partner will be responsible for the commercialisation and manufacture of Vectura's VR315 combination asthma/COPD therapy product, as well as clinical development. Vectura will provide support for the US development of VR315, for which it will receive an initial payment of $10m, and up to $35m upon achievement of pre-determined development milestones. In addition, Vectura will receive a royalty from all VR315 US sales. Dr. Chris Blackwell, Chief Executive of Vectura, said: "This deal provides Vectura with an excellent partner, with a strong track record in respiratory product development and commercialisation, committed to the successful development of VR315 for the lucrative US market."VR315 is a combination therapy for asthma/COPD delivered using Vectura's proprietary technology. The share price was +2.00% to 102.00p at 13:06 NR